- Home
- CNC vs INCY Comparison
CNC vs INCY Comparison
Compare CNC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNC
- INCY
- Stock Information
- Founded
- CNC 1984
- INCY 1991
- Country
- CNC United States
- INCY United States
- Employees
- CNC N/A
- INCY N/A
- Industry
- CNC Medical Specialities
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- CNC Health Care
- INCY Health Care
- Exchange
- CNC Nasdaq
- INCY Nasdaq
- Market Cap
- CNC 15.6B
- INCY 13.0B
- IPO Year
- CNC 2001
- INCY 1993
- Fundamental
- Price
- CNC $29.39
- INCY $85.04
- Analyst Decision
- CNC Hold
- INCY Buy
- Analyst Count
- CNC 16
- INCY 20
- Target Price
- CNC $42.20
- INCY $79.44
- AVG Volume (30 Days)
- CNC 16.2M
- INCY 1.9M
- Earning Date
- CNC 07-25-2025
- INCY 07-29-2025
- Dividend Yield
- CNC N/A
- INCY N/A
- EPS Growth
- CNC N/A
- INCY 900.04
- EPS
- CNC 4.07
- INCY 4.37
- Revenue
- CNC $159,560,000,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- CNC $26.60
- INCY $16.26
- Revenue Next Year
- CNC $0.33
- INCY $11.07
- P/E Ratio
- CNC $7.23
- INCY $19.47
- Revenue Growth
- CNC 10.57
- INCY 18.87
- 52 Week Low
- CNC $25.08
- INCY $53.56
- 52 Week High
- CNC $80.59
- INCY $87.24
- Technical
- Relative Strength Index (RSI)
- CNC 48.68
- INCY 68.22
- Support Level
- CNC $28.56
- INCY $84.55
- Resistance Level
- CNC $30.17
- INCY $87.24
- Average True Range (ATR)
- CNC 0.81
- INCY 2.00
- MACD
- CNC 1.09
- INCY 0.23
- Stochastic Oscillator
- CNC 84.58
- INCY 79.61
About CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.